Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

37.97 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Harmony Biosciences Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Stocks Mixed Amid Earnings, Consumer Sentiment Data
Stocks are mixed this afternoon, as investors unpack earnings reports from several bank giants as well as economic data. 
Via Talk Markets
Why Belden Shares Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Sigma Additive Solutions, Inc. (NASDAQ: SASI) shares jumped 196% to $7.34 after the company announced the signing of a definitive agreement for the acquisition of NextTrip Holdings, Inc. 
Via Benzinga
In the world of growth stocks, NASDAQ:HRMY shines as a value proposition.
NASDAQ:HRMY, a growth stock which is not overvalued. 
Via Chartmill
Expert Ratings for Harmony Biosciences
 
Via Benzinga
Why Shares of Harmony Bioscience Are Falling on Friday
The company reported underwhelming phase 3 trial results for Pitolisant to treat idiopathic hypersomnia. 
Via The Motley Fool
Crude Oil Rises Sharply; Citigroup Posts Upbeat Earnings
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling over 1% on Friday. The Dow traded down 0.05% to 33,615.27 while the NASDAQ fell 1.22% to 13,409.29. The S&P 500 also... 
Via Benzinga
Topics Stocks
Why Is Sleep Disorder Related Harmony Biosciences Stock Trading Lower Today?
Harmony Biosciences Holdings Inc (NASDAQ: HRMY) announced topline results from the INTUNE Phase 3 study of pitolisant in patients with idiopathic hypersomnia (IH). 
Via Benzinga
New Possibilities For Cannabinoid Treatments: Acquisition To Transform Neuropsychiatric Disorder Therapies
Healthcare company Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) completed its previously announced acquisition of Zynerba Pharmaceuticals, Inc. 
Via Benzinga
2 Magnificent Growth Stocks to Buy Right Now
These two biotech stocks could be big winners for patient investors. 
Via The Motley Fool
9 Analysts Have This to Say About Harmony Biosciences
 
Via Benzinga
Expert Ratings for Harmony Biosciences
 
Via Benzinga
The Latest Analyst Ratings for Harmony Biosciences
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 25, 2023
 
Via Benzinga
ZYNERBA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Zynerba Pharmaceuticals, Inc. - ZYNE
From Kahn Swick & Foti, LLC
Via Business Wire
Harmony Biosciences's Earnings Outlook
 
Via Benzinga
Analyst Expectations for Harmony Biosciences's Future
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2023
 
Via Benzinga
NASDAQ: HRMY Investor Alert: Investigation over Potential Wrongdoing at Harmony Biosciences Holdings, Inc.
San Diego, CA -- (SBWIRE) -- 08/17/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at Harmony Biosciences Holdings, Inc. 
Via SBWire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Zynerba Pharmaceuticals, Inc. (Nasdaq - ZYNE), Chindata Group Holdings Limited (Nasdaq - CD), Capri Holdings Limited (NYSE – CPRI), Avid® (Nasdaq - AVID)
From Brodsky & Smith LLC
Via GlobeNewswire
Crude Oil Down 1%; Zynerba Pharmaceuticals Shares Spike Higher
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining around 90 points on Monday. The Dow traded down 0.14% to 35,232.62 while the NASDAQ rose 0.66% to 13,735.42. The... 
Via Benzinga
Topics Stocks
Why Is Zynerba Pharmaceuticals (ZYNE) Stock Up 270% Today?
With Harmony Biosciences acquiring Zynerba Pharmaceuticals, ZYNE stock jumped on both the buyout and the underlying therapeutic implications. 
Via InvestorPlace
Health Care Company Harmony Biosciences Announces Acquisition of Zynerba Pharmaceuticals
 
Via Benzinga
A Look Into Healthcare Sector Value Stocks
 
Via Benzinga
Why Zynerba Pharmaceuticals Stock Is Skyrocketing Today?
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) shares are skyrocketing Monday after Harmony Biosciences (NASDAQ: HRMY) announced it will 
Via Benzinga
7 ‘Strong Buy’ Value Stocks You Should Be Loading Up On Now
Although ultra-cheap ideas tend to carry significant risks, these strong buy value stocks offer the endorsement of analysts. 
Via InvestorPlace
Harmony Biosciences (HRMY) Q2 2023 Earnings Call Transcript
HRMY earnings call for the period ending June 30, 2023. 
Via The Motley Fool
Harmony Biosciences Reports Second Quarter 2023 Financial Results and Business Updates
From Harmony Biosciences
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
7 Best High-Growth Stocks to Buy if You’re a Young Investor
If you’re just starting out and have plenty of time to work with, these are the high-growth stocks for young investors. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.